Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
This guide is part of our pillar: Dementia Medications Compared Donepezil Rivastigmine Memantine.
Related guide: Dementia Medications Compared — our comprehensive resource on this topic.
Leqembi vs donepezil is a generational comparison. Donepezil has been around for decades and is cheap, oral, and modest. Leqembi (lecanemab) is new, infused, expensive, and disease-modifying. Both have a role.
Understanding leqembi vs donepezil helps families ask better questions and make calmer decisions. The detail below covers what doctors usually skip when explaining leqembi vs donepezil.
Mechanism
Donepezil boosts acetylcholine to manage symptoms. Leqembi clears amyloid plaque to slow disease.
Stage of Disease
Donepezil works through mild to moderate. Leqembi is approved only for early Alzheimer’s with confirmed amyloid.
Benefit Size
Donepezil: modest cognitive boost for 6 to 12 months. Leqembi: roughly 27 percent slowing of decline over 18 months in trials.
Major Risks
Donepezil: GI upset, bradycardia, weight loss. Leqembi: ARIA-E (brain swelling) and ARIA-H (microbleeds), occasionally life-threatening.
Cost and Logistics
Donepezil: a few dollars a month. Leqembi: roughly 26,000 dollars a year plus infusions every 2 weeks and frequent MRIs.
Frequently Asked Questions
Can you take both?
Yes, and most early Alzheimer’s patients on Leqembi continue donepezil.
Is Leqembi covered by Medicare?
Yes with conditions, including registry enrollment and confirmed amyloid biomarkers.
For more, see Alzheimer’s Association clinical trials.
